De Andrés-Cardelle, FaustoBarge-Caballero, GonzaloLópez-Pérez, ManuelLópez-López, AndreaGonzález-Babarro, EvaGutiérrez-Feijoo, MarioBilbao-Quesada, RaquelGómez-Otero, InésVarela-Román, AlfonsoBouzas-Mosquera, AlbertoCrespo-Leiro, María GenerosaBarge-Caballero, Eduardo2025-06-092025-06-092025-01-19De Andrés-Cardelle F, Barge-Caballero G, López-Pérez M, López-López A, González-Babarro E, Gutiérrez-Feijoo M, Bilbao-Quesada R, Gómez-Otero I, Varela-Román A, Bouzas-Mosquera A, Crespo-Leiro MG, Barge-Caballero E. Usefulness of the Columbia score for predicting outcomes in patients with transthyretin amyloid cardiomyopathy: analysis of the Galician registry of cardiac amyloidosis. Amyloid. 2025 Jun;32(2):145-153.1350-6129http://hdl.handle.net/2183/42207Observational study[Abstract] Aims: To evaluate the predictive value of the Columbia score in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Methods: Observational study based in a prospective, multi-centre registry of patients with ATTR-CM recruited between January-2018 and December-2023 in 7 Spanish hospitals. The Baseline Columbia score was correlated by means of multivariable Cox's regression with study endpoints all-cause death and all-cause death or heart failure (HF) hospitalisation. Discriminative capacity was evaluated by means of Harrell's C statistics and area under 2-year time-dependent receiver-operator curves. Results: We studied 374 patients with ATTR-CM. Columbia score was independently associated with increased risk of all-cause death (adjusted HR per 1 point = 1.30, 95% CI 1.17-1.45) and all-cause death or HF hospitalisation (adjusted HR per 1 point = 1.38, 95% 1.26-1.50). The score showed moderate discriminative capacity for all-cause death (Harrell's C = 0.653) and all-cause death or HF hospitalisation (Harrell's C = 0.697). The area under the 2-year time-dependent receiver-operator curve was 0.594 for all-cause death and 0.669 for all-cause death or HF hospitalisation. Columbia's score was adequately calibrated for both outcomes. Conclusions: We studied the prognostic performance of the Columbia score in a Spanish prospective cohort of patients with ATTR-CM. The score showed adequate calibration and moderate discriminative capacity for predicting death and HF hospitalisations.engThis is an Accepted Manuscript of an article published by Taylor & Francis in Amyloid, available at Taylor & Francis Online.Columbia scoreTranthyretin cardiomyopathyPrognosisjournal articleopen access10.1080/13506129.2025.2453231